​Buchanan client 60° Pharmaceuticals, LLC (60P) recently received approval from the U.S. Food and Drug Administration for 60P's malaria prevention drug, Arakoda™ (tafenoquine). Arakoda™ is the first drug for malaria prevention to be approved in the U.S. in 18 years.

According to 60P's CEO, Dr. Geoffrey Dow, Arakoda's approval "provides the travel medicine community the option to prescribe an anti-malarial, which provides protection in a large spectrum of malaria hot zones while utilizing what is considered by many physicians to be a more compliant dosing regimen. Arakoda™ is a significant addition to the armamentarium for the prevention of malaria." 

Approval of 60P's Arakoda™ represents coordinated assistance from Buchanan's patent, trademark, government relations and FDA groups. As for Buchanan's assistance, Dr. Dow stated that "the service provided by Buchanan was excellent!"